395 related articles for article (PubMed ID: 30070416)
1. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
[TBL] [Abstract][Full Text] [Related]
2. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
[TBL] [Abstract][Full Text] [Related]
3. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.
Rapezzi C; Merlini G; Quarta CC; Riva L; Longhi S; Leone O; Salvi F; Ciliberti P; Pastorelli F; Biagini E; Coccolo F; Cooke RM; Bacchi-Reggiani L; Sangiorgi D; Ferlini A; Cavo M; Zamagni E; Fonte ML; Palladini G; Salinaro F; Musca F; Obici L; Branzi A; Perlini S
Circulation; 2009 Sep; 120(13):1203-12. PubMed ID: 19752327
[TBL] [Abstract][Full Text] [Related]
4. Myocardial Contraction Fraction by M-Mode Echocardiography Is Superior to Ejection Fraction in Predicting Mortality in Transthyretin Amyloidosis.
Rubin J; Steidley DE; Carlsson M; Ong ML; Maurer MS
J Card Fail; 2018 Aug; 24(8):504-511. PubMed ID: 30010028
[TBL] [Abstract][Full Text] [Related]
5. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.
Caponetti AG; Sguazzotti M; Accietto A; Saturi G; Ponziani A; Giovannetti A; Massa P; Ruotolo I; Sena G; Zaccaro A; Parisi V; Bonfiglioli R; Guaraldi P; Gagliardi C; Cortelli P; Galie N; Biagini E; Longhi S
Eur J Prev Cardiol; 2024 May; 31(7):866-876. PubMed ID: 38204330
[TBL] [Abstract][Full Text] [Related]
6. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
[TBL] [Abstract][Full Text] [Related]
7. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
[TBL] [Abstract][Full Text] [Related]
8. Reduced trans-mitral A-wave velocity predicts the presence of wild-type transthyretin amyloidosis in elderly patients with left ventricular hypertrophy.
Yamamura S; Izumiya Y; Ishida T; Onoue Y; Kimura Y; Hanatani S; Araki S; Fujisue K; Sueta D; Kanazawa H; Takashio S; Usuku H; Sugamura K; Sakamoto K; Yamamoto E; Yamamuro M; Yasuda H; Kojima S; Kaikita K; Hokimoto S; Ogawa H; Tsujita K
Heart Vessels; 2017 Jun; 32(6):708-713. PubMed ID: 27882404
[TBL] [Abstract][Full Text] [Related]
9. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.
Rapezzi C; Quarta CC; Obici L; Perfetto F; Longhi S; Salvi F; Biagini E; Lorenzini M; Grigioni F; Leone O; Cappelli F; Palladini G; Rimessi P; Ferlini A; Arpesella G; Pinna AD; Merlini G; Perlini S
Eur Heart J; 2013 Feb; 34(7):520-8. PubMed ID: 22745357
[TBL] [Abstract][Full Text] [Related]
10. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
[TBL] [Abstract][Full Text] [Related]
11. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy.
Bennani Smires Y; Victor G; Ribes D; Berry M; Cognet T; Méjean S; Huart A; Roussel M; Petermann A; Roncalli J; Carrié D; Rousseau H; Berry I; Chauveau D; Galinier M; Lairez O
Int J Cardiovasc Imaging; 2016 Sep; 32(9):1403-1413. PubMed ID: 27240600
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
[TBL] [Abstract][Full Text] [Related]
13. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).
Ruberg FL; Maurer MS; Judge DP; Zeldenrust S; Skinner M; Kim AY; Falk RH; Cheung KN; Patel AR; Pano A; Packman J; Grogan DR
Am Heart J; 2012 Aug; 164(2):222-228.e1. PubMed ID: 22877808
[TBL] [Abstract][Full Text] [Related]
15. Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.
Gallego-Delgado M; González-López E; Muñoz-Beamud F; Buades J; Galán L; Muñoz-Blanco JL; Sánchez-González J; Ibáñez B; Mirelis JG; García-Pavía P
Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):923-930. PubMed ID: 27291669
[TBL] [Abstract][Full Text] [Related]
16. Blood Proteomic Profiling in Inherited (ATTRm) and Acquired (ATTRwt) Forms of Transthyretin-Associated Cardiac Amyloidosis.
Chan GG; Koch CM; Connors LH
J Proteome Res; 2017 Apr; 16(4):1659-1668. PubMed ID: 28196416
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.
Tini G; Milani P; Zampieri M; Caponetti AG; Fabris F; Foli A; Argirò A; Mazzoni C; Gagliardi C; Longhi S; Saturi G; Vergaro G; Aimo A; Russo D; Varrà GG; Serenelli M; Fabbri G; De Michieli L; Palmiero G; Ciliberti G; Carigi S; Sessarego E; Mandoli GE; Ricci Lucchi G; Rella V; Monti E; Gardini E; Bartolotti M; Crotti L; Merli E; Mussinelli R; Vianello PF; Cameli M; Marzo F; Guerra F; Limongelli G; Cipriani A; Perlini S; Obici L; Perfetto F; Autore C; Porto I; Rapezzi C; Sinagra G; Merlo M; Musumeci B; Emdin M; Biagini E; Cappelli F; Palladini G; Canepa M
Eur J Heart Fail; 2023 Jun; 25(6):845-853. PubMed ID: 36907828
[TBL] [Abstract][Full Text] [Related]
18. Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis.
Kleefeld F; Scherret E; Knebel F; Messroghli D; Heidecker B; Wetz C; Schatka I; Barzen G; Tschöpe C; Amthauer H; Hahn K
Amyloid; 2022 Jun; 29(2):92-101. PubMed ID: 34994254
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness.
Damy T; Costes B; Hagège AA; Donal E; Eicher JC; Slama M; Guellich A; Rappeneau S; Gueffet JP; Logeart D; Planté-Bordeneuve V; Bouvaist H; Huttin O; Mulak G; Dubois-Randé JL; Goossens M; Canoui-Poitrine F; Buxbaum JN
Eur Heart J; 2016 Jun; 37(23):1826-34. PubMed ID: 26537620
[TBL] [Abstract][Full Text] [Related]
20. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.
Connors LH; Sam F; Skinner M; Salinaro F; Sun F; Ruberg FL; Berk JL; Seldin DC
Circulation; 2016 Jan; 133(3):282-90. PubMed ID: 26660282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
